FrancophonIA/ELRC3.0 huggingface dataset:
English: You have been given Valdoxan to treat your depression.
Slovenian: Zdravnik vam ga je predpisal za zdravljenje depresije.
English: Valdoxan 25 mg film-coated tablets agomelatine
Slovenian: Valdoxan 25 mg filmsko obložene tablete agomelatin
English: - alcohol use disorder and /or substantial alcohol intake and in patients receiving concomitant medicinal products associated with risk of hepatic injury.
Slovenian: - motnja uporabe alkohola in/ali uživanje znatnih količin alkohola,
English: At the end of treatment (over 6 or 8 weeks), significant efficacy of agomelatine 25-50 mg was demonstrated in 6 out of the ten short-term double-blind placebo-controlled trials.
Slovenian: 25 do 50 mg dokazali v šestih od desetih kratkoročnih, dvojno slepih, s placebom nadzorovanih preskušanjih.
English: Patients responding to 8/10-weeks of acute treatment with open-label agomelatine 25-50 mg once daily were randomised to either agomelatine 25-50 mg once daily or placebo for further 6-months.
Slovenian: ki so se odzivali na odprto 8- do 10-tedensko akutno zdravljenje z agomelatinom v odmerku 25 do
English: These side effects include: - Very common side effects (may affect more than 1 in 10 people) :headache - Common side effects (may affect up to 1 in 10 people): dizziness, sleepiness (somnolence), difficulty in sleeping (insomnia), feeling sick (nausea), diarrhoea, constipation, abdominal pain, back pain, tiredness, anxiety, abnormal dreams, increased levels of liver enzymes in your blood, vomiting, weight increased.
Slovenian: - Pogosti neželeni učinki (lahko se pojavijo pri največ 1 od 10 bolnikov): omotica, zaspanost (somnolenca), težave s spanjem (nespečnost), siljenje na bruhanje (navzea), driska, zaprtje,
English: In a pharmacokinetic study in elderly patients (≥ 65 years), it was showed that at a dose of 25 mg the mean AUC and mean Cmax were about 4-fold and 13-fold higher for patients ≥ 75 years old compared to patients < 75 years old.
Slovenian: (površina pod krivuljo) 4-krat in srednja Cmax (največja koncentracija) 13-krat višji pri bolnikih ≥ 75 let kot pri bolnikih < 75 let.
English: You should discuss with your doctor on the best way of stopping your previous antidepressant medicine when starting Valdoxan.
Slovenian: Ob začetku zdravljenja z zdravilom Valdoxan se morate posvetovati z zdravnikom o najboljšem možnem načinu prenehanja jemanja prejšnjega antidepresiva.
English: There is limited experience with agomelatine overdose.
Slovenian: O prevelikem odmerjanju z agomelatinom je le malo izkušenj.
English: The calendar printed on the blister containing the tablets should help you remembering when you last took a tablet of Valdoxan.
Slovenian: Da ne bi pozabili, kdaj ste nazadnje vzeli tableto zdravila Valdoxan, si lahko pomagate s koledarčkom, natisnjenim na pretisnem omotu s tabletami.
English: - If you get any side effects ,talk to your doctor or pharmacist.
Slovenian: - Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
English: - Rare side effects (may affect up to 1 in 1,000 people): serious skin eruption (erythematous rash), face oedema (swelling) and angioedema (swelling of the face, lips, tongue and/or throat that may cause difficulty in breathing or swallowing), hepatitis, yellow coloration of the skin or the whites of the eyes (jaundice), hepatic failure*, hallucinations, inability to remain still (due to physical and mental unrest), inability to completely empty the bladder.
Slovenian: jezika in/ali žrela, kar lahko povzroči težave pri dihanju ali požiranju), hepatitis, rumeno obarvanje kože in beločnic (zlatenica), odpoved jeter*, halucinacije, nesposobnost biti pri miru
English: What Valdoxan looks like and contents of the pack Valdoxan 25 mg film-coated tablets (tablet) are oblong, orange-yellow with a blue imprint of ‘company logo'
Slovenian: Valdoxan 25 mg filmsko obložene tablete (tablete) so podolgovate, oranžnorumene z modrim odtisom
English: - after around 3 weeks, - after around 6 weeks (end of acute phase), - after around 12 and 24 weeks (end of maintenance phase), - and thereafter when clinically indicated.
Slovenian: • Pogostnost pregledovanja delovanja jeter - pred uvedbo zdravljenja - in nato: - po približno 3 tednih, - po približno 6 tednih (na koncu akutne faze), - po približno 12 in 24 tednih (na koncu vzdrževalne faze)
English: Musculoskeletal and connective tissue disorders
Slovenian: Bolezni mišično-skeletnega sistema in vezivnega tkiva pogosti bolečine v hrbtu
English: There is no data on the influence of race on agomelatine pharmacokinetics.
Slovenian: Podatkov o vplivu etnične pripadnosti na farmakokinetiko agomelatina ni. 5.3 Predklinični podatki o varnosti
English: NAME OF THE MEDICINAL PRODUCT Valdoxan 25 mg tablets agomelatine
Slovenian: IME ZDRAVILA Valdoxan 25 mg tablete agomelatin
English: Tel: +371 67502039
Slovenian: SIA Servier Latvia Tel: +371 67502039
English: How to store Valdoxan
Slovenian: Shranjevanje zdravila Valdoxan
English: 1 NAME OF THE MEDICINAL PRODUCT Valdoxan 25 mg film-coated tablets
Slovenian: IME ZDRAVILA Valdoxan 25 mg filmsko obložene tablete
English: • A blood tests appointments reminder.
Slovenian: • navodila v obliki sheme spremljanja delovanja jeter • opomnik za dogovorjene datume laboratorijskih preiskav.
English: - The other ingredients are:
Slovenian: Pojav takšnih misli je verjetnejši:
English: Back pain
Slovenian: PET SOB NED
English: Migraine
Slovenian: Zdravljenje
English: No hepatotoxicity was observed in rodents and monkeys in the repeat dose toxicity studies.
Slovenian: Toksikološke študije z večkratnim odmerjanjem pri glodalcih in opicah niso pokazale hepatotoksičnosti.
English: You should not take Valdoxan together with certain medicines (see also under “Do not take Valdoxan” in section 2): fluvoxamine (another medicine used in the treatment of depression), ciprofloxacin (an antibiotic) can modify the expected dose of agomelatine in your blood.
Slovenian: Valdoxan« v poglavju 2): fluvoksamin (še enim zdravilom za zdravljenje depresije), ciprofloksacin
English: Following oral administration, agomelatine is rapidly metabolised mainly via hepatic CYP1A2; CYP2C9 and CYP2C19 isoenzymes are also involved but with a low contribution.
Slovenian: Izoencima CYP2C9 in CYP2C19 prav tako sodelujeta, vendar v manjši meri.
English: Povidone (K30) Sodium starch glycolate type A Stearic acid
Slovenian: Jedro tablete - laktoza monohidrat - koruzni škrob - povidon (K30) - natrijev karboksimetilškrob (vrsta A) - stearinska kislina - magnezijev stearat - brezvoden koloidni silicijev dioksid
English: Experience with agomelatine in overdose has indicated that epigastralgia, somnolence, fatigue, agitation, anxiety, tension, dizziness, cyanosis or malaise have been reported.
Slovenian: Pri izkušnjah s prevelikim odmerjanjem agomelatina so poročali o bolečini v epigastričnem predelu, somnolenci, utrujenosti,
English: No relevant modification of pharmacokinetic parameters in patients with severe renal impairment has been observed (n=8, single dose of 25 mg), but caution should be exercised in patients with severe or moderate renal impairment as only limited clinical data are available in these patients (see section 4.2).
Slovenian: Pri bolnikih s hudo ledvično okvaro niso opazili pomembnih sprememb farmakokinetičnih parametrov (n = 8, enkratni odmerek 25 mg).
English: Breastfeeding should be discontinued if you take Valdoxan.
Slovenian: Če jemljete zdravilo Valdoxan, morate prenehati z dojenjem.
English: Close supervision of patients and in particular those at high risk should accompany treatment especially in early treatment and following dose changes.
Slovenian: Med zdravljenjem, še posebej pri uvedbi zdravljenja in pri vsaki spremembi odmerka, je treba bolnike skrbno nadzirati.
English: There is no experience of concurrent use of agomelatine with ECT.
Slovenian: Ni izkušenj z jemanjem agomelatina sočasno z elektrokonvulzivnim zdravljenjem.
English: Ear and labyrinth disorders
Slovenian: Ušesne bolezni, vključno z motnjami labirinta občasni tinitus*
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton
Slovenian: PODATKI NA ZUNANJI OVOJNINI Škatla
English: United Kingdom Servier Laboratories Ltd
Slovenian: France Les Laboratoires Servier
English: Information from clinical trials has shown an increased risk of suicidal behaviour in young adults (aged less than 25 years) with psychiatric conditions who were being treated with an antidepressant.
Slovenian: (mlajših od 25 let) z motnjami razpoloženja med zdravljenjem z antidepresivi obstaja večje tveganje za pojav samomorilnega vedenja.
English: In clinical trials among children and adolescents treated with other antidepressants, suicide-related behaviour (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed compared to those treated with placebo (see section 4.2).
Slovenian: Samomorilno vedenje (poskuse samomora in samomorilne misli) ter sovražnost (predvsem napadalnost,
English: • A guidance on the scheme of hepatic monitoring
Slovenian: • Navodila v primeru, ko pregled delovanja jeter pokaže nepravilnosti;
English: BATCH NUMBER Batch
Slovenian: ŠTEVILKA SERIJE Lot:
English: - If you are obese or overweight, ask your doctor for advice.
Slovenian: Posvetujte se z zdravnikom, katera zdravila so to. - Če ste debeli ali imate prekomerno telesno maso, se posvetujte s svojim zdravnikom.
English: Dizziness Somnolence Insomnia
Slovenian: Očesne bolezni občasni zamegljen vid
English: Urinary retention*
Slovenian: Bolezni sečil redki zadrževanje urina*
English: Further information on Edistride can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Edistride.
Slovenian: Nadaljnje informacije o zdravilu Edistride so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Edistride.
English: This authorisation was based on the authorisation granted for Forxiga in 2012.
Slovenian: Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom Forxiga, ki je bilo izdano leta 2012.
English: What measures are being taken to ensure the safe and effective use of Edistride?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Edistride?
English: Edistride received a marketing authorisation valid throughout the EU on 9 November 2015.
Slovenian: Za zdravilo Edistride je bilo 9. novembra 2015 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
English: Other information about Edistride
Slovenian: Druge informacije o zdravilu Edistride
English: An overview of Edistride and why it is authorised in the EU
Slovenian: Pregled zdravila Edistride in zakaj je odobreno v EU
English: As for all medicines, data on the use of Edistride are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Edistride stalno spremljajo.
English: For type 2 diabetes, the dose of Edistride is 10 mg once a day.
Slovenian: Pri sladkorni bolezni tipa 2 znaša odmerek Edistride 10 mg enkrat na dan.
English: Why is Edistride authorised in the EU?
Slovenian: Zakaj je zdravilo Edistride odobreno v EU?
English: The Agency concluded that the benefits of Edistride outweigh its risks and recommended that it be granted marketing authorisation.
Slovenian: Agencija je zaključila, da so koristi zdravila Edistride večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
English: Side effects reported with Edistride are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Edistride, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Edistride is available as tablets (5 and 10 mg) and can only be obtained with a prescription.
Slovenian: Zdravilo Edistride je na voljo v obliki tablet (5 in 10 mg), njegovo predpisovanje in izdaja pa je le na recept.
English: What benefits of Edistride have been shown in studies?
Slovenian: Kakšne koristi zdravila Edistride so se pokazale v študijah?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Edistride have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Edistride upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: The company that markets Edistride will provide information on precautions to prevent diabetic ketoacidosis in patients with type 1 diabetes, including a patient alert card, and a guide for patients and their carers, as well as a guide for healthcare professionals, including a prescriber's checklist.
Slovenian: Podjetje, ki trži zdravilo Edistride, bo zagotovilo informacije o previdnostnih ukrepih za preprečevanje diabetične ketoacidoze pri bolnikih s sladkorno boleznijo tipa 1, vključno z opozorilno kartico za bolnika, in vodnik za bolnike in njihove negovalce ter navodila za zdravstvene delavce, vključno s kontrolnim seznamom za zdravnike, ki bodo predpisovali zdravilo.
English: For more information about using Edistride, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Edistride glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: What is Edistride and what is it used for?
Slovenian: Kaj je zdravilo Edistride in za kaj se uporablja?
English: What are the risks associated with Edistride?
Slovenian: Kakšna tveganja so povezana z zdravilom Edistride?
English: Diabetes can occur when the body does not make enough insulin to control the amount of glucose (sugar) in the blood or when the body is cannot use insulin effectively.
Slovenian: Sladkorna bolezen se lahko pojavi, kadar telo ne proizvaja dovolj insulina za uravnavanje primerne ravni glukoze (sladkorja) v krvi ali kadar ga telo ne more učinkovito izrabiti.
English: Precautions have been recommended to reduce the risk of diabetic ketoacidosis and the Agency has asked for further studies to determine its frequency in patients with type 1 diabetes treated with Edistride.
Slovenian: Priporočeni so bili previdnostni ukrepi za zmanjšanje tveganja diabetične ketoacidoze, agencija pa je zaprosila za nadaljnje študije, da bi ugotovila njeno pogostnost pri bolnikih s sladkorno boleznijo tipa 1, ki so bili zdravljeni z zdravilom Edistride.
English: In type 2 diabetes, it is used with appropriate diet and exercise in patients who cannot take metformin (another diabetes medicine).
Slovenian: Pri sladkorni bolezni tipa 2 se skupaj z ustrezno dieto in telesno vadbo uporablja pri bolnikih, ki ne morejo jemati metformina (drugega zdravila za zdravljenje sladkorne bolezni).
English: The most common side effect in patients with type 1 diabetes (which may affect up to 1 in 10 people) is genital infection, especially in women and a common side effect (which may affect up to 1 in 100 people) is diabetic ketoacidosis.
Slovenian: Najpogostejši neželeni učinek pri bolnikih s sladkorno boleznijo tipa 1 (ki se lahko pojavijo pri največ 1 bolniku od 10) so okužbe spolovil, zlasti pri ženskah, pogost neželeni učinek (ki se lahko pojavi pri 1 bolniku od 100) pa je diabetična ketoacidoza.
English: In type 1 diabetes, Edistride is used with insulin in overweight patients (body mass index of at least 27 kg/m2) when insulin on its own does not control the diabetes well enough.
Slovenian: Pri sladkorni bolezni tipa 1 se zdravilo Edistride uporablja skupaj z insulinom pri bolnikih s prekomerno telesno maso (z indeksom telesne mase vsaj 27 kg/m2), če insulin sam ne zadostuje za ustrezno uravnavanje sladkorne bolezni.
English: Edistride is a diabetes medicine used for adults whose condition is not controlled well enough.
Slovenian: Edistride je zdravilo za zdravljenje sladkorne bolezni pri odraslih bolnikih, katerih bolezen ni zadostno uravnana.
English: If it is used with insulin or medicines that help the body produce insulin, the doses of these other medicines may need to be reduced to decrease the risk of hypoglycaemia (low blood sugar levels).
Slovenian: Če se uporablja v kombinaciji z insulinom ali zdravili, ki spodbujajo tvorbo insulina, bo za zmanjšanje tveganja hipoglikemije (nizke ravni sladkorja v krvi) morda treba njihov odmerek zmanjšati.
English: Edistride was found effective in several studies in patients with type 2 and type 1 diabetes.
Slovenian: Zdravilo Edistride se je izkazalo za učinkovito v več študijah pri bolnikih s sladkorno boleznijo tipa 2 ali tipa 1.
English: In a study involving 814 patients with type 2 diabetes, Edistride used in combination with metformin was at least as effective as a sulphonylurea (another type of diabetes medicines) used with metformin.
Slovenian: V študiji pri 814 bolnikih s sladkorno boleznijo tipa 2 je bilo zdravilo Edistride v kombinaciji z metforminom vsaj tako učinkovito kot sulfonilsečnina (druga vrsta zdravila za zdravljenje sladkorne bolezni) v kombinaciji z metforminom.
English: For type 1 diabetes, treatment with Edistride should be started and supervised by a specialist in type 1 diabetes.
Slovenian: Pri sladkorni bolezni tipa 1 mora zdravljenje z zdravilom Edistride uvesti in nadzorovati zdravnik specialist za sladkorno bolezen tipa 1.
English: The most common side effect with Edistride in patients with type 2 diabetes (which may affect more than 1 in 10 people) is hypoglycaemia, especially when used in combination with a sulphonylurea or insulin.
Slovenian: Najpogostejši neželeni učinek zdravila Edistride pri bolnikih s sladkorno boleznijo tipa 2 (ki se lahko pojavijo pri več kot 1 bolniku od 10) je hipoglikemija, zlasti kadar se zdravilo uporablja v kombinaciji s sulfonilsečnino ali insulinom.
English: The company will also conduct a study to estimate the frequency of diabetic ketoacidosis in patients with type 1 diabetes treated with Edistride.
Slovenian: Izvedla bo tudi študijo za oceno pogostnosti diabetične ketoacidoze pri bolnikih s sladkorno boleznijo tipa 1, zdravljenih z zdravilom Edistride.
English: Edistride's common side effects were related to the way the medicine works, such as increased genital and, to a smaller degree, urinary infection, and are considered manageable.
Slovenian: Pogosti neželeni učinki zdravila Edistride so povezani z načinom delovanja zdravila, npr. več okužb spolovil in v nekoliko manj primerih okužb sečil, vendar jih je mogoče obvladati.
English: For the full list of side effects and restrictions with Edistride, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Edistride glejte navodilo za uporabo.
English: In two studies involving 1,648 patients with type 1 diabetes whose blood sugar was not controlled well enough on insulin alone, adding Edistride 5 mg decreased HbA1c levels after 24 hours by 0.37% and by 0.42% more than adding placebo.
Slovenian: V dveh študijah, v katerih je sodelovalo 1 648 bolnikov s sladkorno boleznijo tipa 1, pri katerih sladkor v krvi ni bil zadovoljivo uravnan samo z insulinom, je zdravilo Edistride v odmerku 5 mg po 24 urah znižalo ravni HbA1c za 0,37 % in za 0,42 % več kot placebo.
English: The active substance in Edistride, dapagliflozin, blocks the action of a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2).
Slovenian: Učinkovina v zdravilu Edistride, dapagliflozin, zavira beljakovino v ledvicah, imenovano natrij-glukozni soprenašalec 2 (SGLT2).
English: How is Edistride used?
Slovenian: Kako se zdravilo Edistride uporablja?
English: Adding Edistride to insulin treatment in patients with type 1 diabetes whose diabetes could not be controlled well enough with insulin was also effective.
Slovenian: Dodajanje zdravila Edistride insulinu pri bolnikih s sladkorno boleznijo tipa 1, pri katerih sladkor v krvi ni zadovoljivo uravnan samo z insulinom, se je ravno tako izkazalo za učinkovito.
English: By blocking the action of SGLT2, dapagliflozin causes the kidney to pass out more glucose in the urine, thereby reducing the levels of glucose in the blood.
Slovenian: Dapagliflozin z zaviranjem delovanja soprenašalca SGLT2 poveča izločanje glukoze z urinom, kar zniža njene ravni v krvi.
English: In four other studies involving 2,370 patients, adding Edistride to other diabetes medicines decreased HbA1c levels by 0.54-0.68 percentage points more than adding placebo after 24 weeks.
Slovenian: V štirih dodatnih študijah, v katerih je sodelovalo 2 370 bolnikov, je dodajanje zdravila Edistride drugim zdravilom za zdravljenje sladkorne bolezni po 24 tednih znižalo ravni HbA1c za od 0,54 do 0,68 odstotnih točk več kot dodajanje placeba.
English: The European Medicines Agency considered that Edistride was effective for treating type 2 diabetes when given alone or in combination with other diabetes medicines which work in different ways.
Slovenian: Evropska agencija za zdravila je zaključila, da je zdravilo Edistride učinkovito pri zniževanju ravni glukoze v krvi pri bolnikih s sladkorno boleznijo tipa 2, kadar se uporablja kot samostojno zdravilo ali v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni z drugačnimi mehanizmi delovanja.
English: Edistride increased the risk of diabetic ketoacidosis considerably in patients with type 1 diabetes and it is recommended for this condition only in overweight and obese patients.
Slovenian: Zdravilo Edistride je pri bolnikih s sladkorno boleznijo tipa 1 močno povečalo tveganje diabetične ketoacidoze, zato se zanje priporoča le v primeru močno prevelike telesne mase.
English: How does Edistride work?
Slovenian: Kako zdravilo Edistride deluje?
English: In two studies involving 840 patients with type 2 diabetes, Edistride when used alone decreased HbA1c levels by 0.66 percentage points more than placebo (a dummy treatment) after 24 weeks.
Slovenian: Zdravilo Edistride, uporabljeno samostojno, je v dveh študijah, v kateri je bilo vključenih 840 bolnikov s sladkorno boleznijo tipa 2, po 24 tednih znižalo ravni HbA1c za 0,66 odstotnih točk več kot placebo (zdravilo brez učinkovine).
English: In addition, beneficial reductions in weight and blood pressure occurred in patients treated with Edistride.
Slovenian: Poleg tega se je pri bolnikih, zdravljenih z zdravilom Edistride, korist zdravila pokazala tudi pri znižanju telesne mase in krvnega tlaka.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Dasselta on 28 November 2011.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Dasselta, veljavno po vsej Evropski uniji, odobrila dne 28. novembra 2011.
English: This means that Dasselta is similar to a ‘reference medicine' already authorised in the European Union (EU) called Aerius.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Aerius.
English: The full EPAR for Dasselta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Dasselta je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What are the benefits and risks of Dasselta?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Dasselta?
English: This is a summary of the European public assessment report (EPAR) for Dasselta.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Dasselta.
English: Other information about Dasselta
Slovenian: Druge informacije o zdravilu Dasselta
English: For more information about treatment with Dasselta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Dasselta preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.